Pharmacokinetics of fosfomycin in chickens after a single intravenous dose and tissue levels following chronic oral administration.
This paper describes the pharmacokinetics of fosfomycin following a single i.v. bolus dose (10 mg/kg of body weight) in broiler chickens. Serial blood samples were collected up to 5 h post-administration. Fosfomycin serum concentrations were determined by a microbiological method, using Proteus mirabilis as the test microorganism. The serum concentration versus time curves after i.v. administration followed a biexponential decline. The main pharmacokinetic variables were t1/2 lambda l = 23 min, t1/2 lambda n = 112 min, VDarea = 575 +/- 190 mL/kg and CLb = 3.12 +/- 0.44 mL.min-1.kg-1. Tissue levels of fosfomycin in kidney, liver, lung, muscle, heart, fat, gizzard and serum were also determined after oral chronic administration of the drug in drinking water (150 micrograms/mL). During the oral chronic administration period, high FOS concentrations in serum were maintained (mean 6.1 +/- 1.1 micrograms/mL), but a significant decline over time could be observed (P < 0.05). Fosfomycin was detected in all tissues except muscle, with mean concentrations ranging from 0.63 microgram/g in fat to 13.48 micrograms/g in kidney. Twenty-four hours after the treatment was finished, fosfomycin levels were below the assay detection limit in all tissues tested.
Aramayona
J J
JJ
Department of Pharmacology and Physiology, Veterinary Faculty, University of Zaragoza, Spain. aramayon@posta.unizar.es
Bregante
M A
MA
Solans
C
C
Rueda
S
S
Fraile
L J
LJ
Garcia
M A
MA
D000273:Adipose Tissue / Q000737:chemistry / Q000378:metabolism; D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000032:analysis* / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001835:Body Weight / Q000502:physiology; D002645:Chickens / Q000097:blood / Q000378:metabolism* / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D005578:Fosfomycin / Q000008:administration & dosage / Q000032:analysis* / Q000493:pharmacokinetics*; D005895:Gizzard, Avian / Q000737:chemistry / Q000378:metabolism; D006207:Half-Life; D007275:Injections, Intravenous / Q000379:methods / Q000662:veterinary; D007668:Kidney / Q000737:chemistry / Q000378:metabolism; D008099:Liver / Q000737:chemistry / Q000378:metabolism; D008168:Lung / Q000737:chemistry / Q000378:metabolism; D008826:Microbial Sensitivity Tests / Q000662:veterinary; D008954:Models, Biological; D018482:Muscle, Skeletal / Q000737:chemistry / Q000378:metabolism; D009206:Myocardium / Q000737:chemistry / Q000378:metabolism; D011513:Proteus mirabilis / Q000187:drug effects; D013997:Time Factors; D014018:Tissue Distribution
D000900:Anti-Bacterial Agents; D005578:Fosfomycin